Psychedelics

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

Cybin announces receipt of its "may proceed letter" from the U.S. Food and Drug Administration (FDA) regarding its Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).

TSI EDITOR | 2022-06-27

---

Numinus Pilots Mental Health Program for Corporate Clients in Utah

Numinus announces a pilot program to encourage employers to offer ketamine-assisted psychotherapy to employees as a health benefit.

TSI EDITOR | 2022-06-23

---

Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

Cybin Inc reports its fiscal year 2022 financial results, including progress on several pipeline initiatives, with a cash balance of CAD$53.6 million as of March 31, 2022.

TSI EDITOR | 2022-06-22

---

BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum

Better Life Pharma will be presenting an abstract on its lead compound, BETR-001, to the European Neuroscience Societies (FENS) Forum in July.

TSI EDITOR | 2022-06-21

---

Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics

Optimi files an application with Health Canada to synthesize, process and produce pharmaceutical grade 3,4-Methylenedioxymethamphetamine ("MDMA").

TSI EDITOR | 2022-06-20

---

Numinus completes acquisition of Novamind and announces executive appointments

Numinus Wellness announces the completion of its acquisition of Novamind Inc, with Novamind shareholders receiving 0.84 shares of Numinus per Novamind share.

TSI EDITOR | 2022-06-10

---

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin Inc announces acquiring a Phase 1 DMT study from Entheon Biomedical, at a purchase price of CAD$1 million plus additional considerations.

TSI EDITOR | 2022-06-07

---

Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder

Cybin Inc announces the submission of an Investigational New Drug application (IND) to the FDA for a Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).

TSI EDITOR | 2022-05-31

---

Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

Optimi Health announces a new supply agreement with Filament Health to supply Filament with psilocybin mushrooms.

TSI EDITOR | 2022-05-31

---

Novamind Reports Fiscal Q3 2022 Financial Results and Operating Highlights

Novamind Inc reports its Q3 for fiscal 2022. Quarterly revenues of CAD$3,227,352 represent a q-o-q of 32%. Novamind also expanded into the Arizona market in Q2 with its clinic operations.

TSI EDITOR | 2022-05-31

---

• 1
• 2
• 3
• 4
• ...
• 60
• Next